Roche to file MS drug for approval in early 2016; Bristol-Myers' Opdivo scores Early Access spot in U.K.; Boehringer diabetes med falls short in Phase II;

> Roche ($RHHBY) touted success for its MS drug ocrelizumab in two late-stage studies, saying the data puts it on track for regulatory filings in early 2016. Report

> Bristol-Myers Squibb's ($BMY) new cancer immuno-therapy Opdivo scored a spot on the U.K.'s Early Access to Medicines Scheme, the first lung cancer drug to be approved under the program. Report

> Boehringer Ingelheim and its development partner Vitae ($VTAE) saw their diabetes drug VTP-34072 fail to significantly decrease blood sugar in a mid-stage trial. Report

> AstraZeneca's ($AZN) Crestor patent was invalidated by the Brazilian federal courts. Report

> Novartis' ($NVS) eye care unit Alcon won European approval for a new type of lens used in cataract surgery. Release

> Cosmederm Bioscience expanded its itch-relief product line TriClam with two new topical products. Release

And Finally... WPP-owned brand agency The Partners appointed Peter Henshaw from Inventiv Europe as a creative director for its health team. Report